Risk factors for carbapenem-resistant Klebsiella pneumoniae infection/colonization: A case-case-control study

Journal of Infection and Chemotherapy

Volumn 20, Issue 5, 2014, Pages 293-297

  Kofteridis, Diamantis P ^a   Valachis, Antonis ^a   Dimopoulou, Dimitra ^a   Maraki, Sofia ^a   Christidou, Athanasia ^a   Mantadakis, Elpis ^b   Samonis, George ^a  

^a UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

^b DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

Author keywords

Antimicrobial resistance; Carbapenem resistant Klebsiella; Intensive care unit; Pneumoniae; Renal disease

Indexed keywords

CARBAPENEM; CARBAPENEM DERIVATIVE;

ADULT; AGED; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL COLONIZATION; BACTERIUM ISOLATION; BLOOD; CARBAPENEM RESISTANT ENTEROBACTERIACEAE; CASE CONTROL STUDY; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; GREECE; HUMAN; KIDNEY DISEASE; KLEBSIELLA PNEUMONIAE INFECTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; NEUROLOGIC DISEASE; RETROSPECTIVE STUDY; RISK FACTOR; URINE; VERY ELDERLY; DRUG EFFECTS; KLEBSIELLA INFECTIONS; KLEBSIELLA PNEUMONIAE; MIDDLE AGED;

ADULT; AGED; AGED, 80 AND OVER; CARBAPENEMS; CASE-CONTROL STUDIES; DRUG RESISTANCE, BACTERIAL; FEMALE; HUMANS; KLEBSIELLA INFECTIONS; KLEBSIELLA PNEUMONIAE; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 84903723112     PISSN: 1341321X     EISSN: 14377780     Source Type: Journal    
DOI: 10.1016/j.jiac.2013.11.007     Document Type: Article

References (37)

1. Bradford P, Bratu S, Urban C, Visalli M, Mariano N, Landman D, et al. Emergence of carbapenem-resistant Klebsiella species possessing the class A carbapenem-hydrolyzing KPC-2 and inhibitor-resistant TEM-30 B-lactamases in New York City. Clin Infect Dis 2004;39: 55-60.
2. Bratu S, Landman D, Haag R, Recco R, Eramo A, Alam M, et al. Rapid spread of carbapenem-resistant Klebsiella pneumoniae in New York City: a new threat to our antibiotic armamentarium. Arch Intern Med 2005;165: 1430-5.
3. Bratu S, Mooty M, Nichani S, Landman D, Gullans C, Pettinato B, et al. Emergence of KPC-possessing Klebsiella pneumoniae in Brooklyn, New York: epidemiology and recommendations for detection. Antimicrob Agents Chemother 2005;49: 3018-20.
4. Giakkoupi P, Xanthaki A, Kanelopoulou M, Vlahaki A, Miriagou V, Kontou S, et al. VIM-1 metallo-beta-lactamase-producing Klebsiella pneumoniae strains in Greek hospitals. J Clin Microbiol 2003;41: 3893-6.
5. Ikonomidis A, Tokatlidou D, Kristo I, Sofianou D, Tsakris A, Mantzana P, et al. Outbreaks in distinct regions due to a single Klebsiella pneumoniae clone carrying a blaVIM-1 metallo-{beta}-lactamase gene. J Clin Microbiol 2005;43: 5344-7.
6. Woodford N, Tierno Jr PM, Young K, Tysall L, Palepou MF, Ward E, et al. Outbreak of Klebsiella pneumoniae producing a new carbapenem-hydrolyzing class A beta-lactamase, KPC-3, in a New York medical center. Antimicrob Agents Chemother 2004;48: 4793-9.
7. Yigit H, Queenan AM, Anderson GJ, Domenech-Sanchez A, Biddle JW, Steward CD, et al. Novel carbapenem-hydrolyzing beta-lactamase, KPC-1, from a carbapenem-resistant strain of Klebsiella pneumoniae. Antimicrob Agents Chemother 2001;45: 1151-61.
8. Schwaber M, Klarfeld-Lidji S, Navon-Venezia S, Schwartz D, Leavitt A, Carmeli Y. Predictors of carbapenem-resistant Klebsiella pneumoniae acquisition among hospitalized adults, and effect of acquisition on mortality. Antimicrob Agents Chemother 2008;52: 1028-33.
9. Bratu S, Brooks S, Burney S, Kochar S, Gupta J, Landman D, et al. Detection and spread of Escherichia coli possessing the plasmid-borne carbapenemase KPC-2 in Brooklyn, New York. Clin Infect Dis 2007;44: 972-5.
10. Kaye KS, Harris AD, Samore M, Carmeli Y. The case-case-control study design: addressing the limitations of risk factor studies for antimicrobial resistance. Infect Control Hosp Epidemiol 2005;26: 346-51.
11. Falagas ME, Rafailidis PI, Kofteridis D, Virtzili S, Chelvatzoglou FC, Papaioannou V, et al. Risk factors of carbapenem-resistant Klebsiella pneumoniae infections: a matched case-control study. J Antimicrob Chemother 2007;60: 1124-30.
12. Patel G, Huprikar S, Factor SH, Jenkins SG, Calfee DP. Outcomes of carbapenem-resistant Klebsiella pneumoniae infection and the impact of antimicrobial and adjunctive therapies. Infect Control Hosp Epidemiol 2008;29: 1099-106.
13. Hussein K, Sprecher H, Mashiach T, Oren I, Kassis I, Finkelstein R. Carbapenem resistance among Klebsiella pneumoniae isolates: risk factors, molecular characteristics, and susceptibility patterns. Infect Control Hosp Epidemiol 2009;30: 666-71.
14. Gasink LB, Edelstein PH, Lautenbach E, Synnestvedt M, Fishman NO. Risk factors and clinical impact of Klebsiella pneumoniae carbapenemase-producing K. pneumoniae. Infect Control Hosp Epidemiol 2009;30: 1180-5.
15. Kwak YG, Choi SH, Choo EJ, Chung JW, Jeong JY, Kim NJ, et al. Risk factors for the acquisition of carbapenem-resistant Klebsiella pneumoniae among hospitalized patients. Microb Drug Resist 2005;11: 165-9.
16. Borer A, Saidel-Odes L, Riesenberg K, Eskira S, Peled N, Nativ R, et al. Attributable mortality rate for carbapenem-resistant Klebsiella pneumoniae bacteremia. Infect Control Hosp Epidemiol 2009;30: 972-6.
17. Kritsotakis EI, Tsioutis C, Roumbelaki M, Christidou A, Gikas A. Antibiotic use and the risk of carbapenem-resistant extended-spectrum-{beta}- lactamase- producing Klebsiella pneumoniae infection in hospitalized patients: results of a double case-control study. J Antimicrob Chemother 2011;66: 1383-91.
18. Kaye KS, Harris AD, Gold H, Carmelli Y. Risk factors for recovery of ampicillinsulbactam- resistant Escherichia coli in hospitalized patients. Antimicrob Agents Chemother 2000;44: 1004-9.
19. Harris AD, Prevencevich E, Roghmann MC, Morris G, Kaye KS, Johnson JA. Risk factors for piperacillin-tazobactam-resistant Pseudomonas aeruginosa among hospitalized patients. Antimicrob Agents Chemother 2002;46: 854-8.
20. Farmer 3rd JJ, Boatwright KD, Janda JM. Enterobacteriaceae: introduction and identification. In: Murray P, Baron EJ, Jorgensen JH, Landry ML, Pfaller MA, editors. Manual of clinical microbiology. Washington, DC: ASM Press; 2007. pp. 649-69.
21. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. Twenty-first informational supplement. Document M100-S21. Wayne, PA: CLSI; 2011.
22. Paterson DL, Bonomo RA. Extended-spectrum beta-lactamases: a clinical update. Clin Microbiol Rev 2005;18: 657-86.
23. Maltezou HC, Giakkoupi P, Maragos A, Bolikas M, Raftopoulos V, Papahatzaki H, et al. Outbreak of infections due to KPC-2 producing Klebsiella pneumoniae in a hospital in Crete (Greece). J Infect 2009;58: 213-9.
24. Giakkoupi P, Maltezou H, Polemis M, Pappa O, Saroglou G, Vatopoulos A, Greek System for the Surveillance of Antimicrobial Resistance. KPC-2 producing Klebsiella pneumoniae infections in Greek hospitals is mainly due to a hyperepidemic clone. Euro Surveill 2009;14. pii:19218.
25. Papadimitriou-Olivgeris M, Marangos M, Fligou F, Christofidou M, Bartzavali C, Anastassiou ED, et al. Risk factors for KPC-producing Klebsiella pneumoniae enteric colonization upon ICU admission. J Antimicrob Chemother 2012;67: 2976-81.
26. Papadimitriou-Olivgeris M, Marangos M, Fligou F, Christofidou M, Sklavou C, Vamvakopoulou S, et al. KPC-producing Klebsiella pneumoniae enteric colonization acquired during intensive care unit stay: the significance of risk factors for its development and its impact on mortality. Diagn Microbiol Infect Dis 2013;77: 169-73.
27. Zarkotou O, Pournaras S, Voulgari E, Chrysos G, Prekates A, Voutsinas D, et al. Risk factors and outcomes associated with acquisition of colistin-resistant KPC-producing Klebsiella pneumoniae: a matched case-control study. J Clin Microbiol 2010;48: 2271-4.
28. Tacconelli E. Antimicrobial use: risk driver of multidrug resistant microorganisms in healthcare settings. Curr Opin Infect Dis 2009;22: 352-8.
29. Mulvey MR, Simor AE. Antimicrobial resistance in hospitals: how concerned should we be? CMAJ 2009;180: 408-15.
30. Monnet DL, Archibald LK, Phillips L, Tenover FC, McGowan Jr JE, Gaynes RP. Antimicrobial use and resistance in eight US hospitals: complexities of analysis and modeling. Intensive Care Antimicrobial Resistance Epidemiology Project and National Nosocomial Infections Surveillance System Hospitals. Infect Control Hosp Epidemiol 1998;19: 388-94.
31. Hyle EP, Lipworth AD, Zaoutis TE, Nachamkin I, Fishman NO, Bilker WB, et al. Risk factors for increasing multidrug resistance among extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella species. Clin Infect Dis 2005;40: 1317-24.
32. Brusselaers N, Vogelaers D, Blot S. The rising problem of antimicrobial resistance in the intensive care unit. Ann Intensive Care 2011;1:47.
33. Naqvi SB, Collins AJ. Infectious complications in chronic kidney disease. Adv Chronic Kidney Dis 2006;13: 199-204.
34. Gardner ID. The effect of aging on susceptibility to infection. Rev Infect Dis 1980;2: 801-10.
35. Zarkotou O, Pournaras S, Tselioti P, Dragoumanos V, Pitiriga V, Ranellou K, et al. Predictors of mortality in patients with bloodstream infections caused by KPC-producing Klebsiella pneumoniae and impact of appropriate antimicrobial treatment. Clin Microbiol Infect 2011;17: 1798-803.
36. Daikos GL, Markogiannakis A. Carbapenemase-producing Klebsiella pneumoniae: (when) might we still consider treating with carbapenems? Clin Microbiol Infect 2011;17: 1135-41.
37. Patel N, McNutt LA, Lodise TP. Relationship between various definitions of prior antibiotic exposure and piperacillin-tazobactam resistance among patients with respiratory tract infections caused by Pseudomonas aeruginosa. Antimicrob Agents Chemother 2008;52: 2933-6.